John G Ullman & Associates Inc. Sells 3,512 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

John G Ullman & Associates Inc. lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,300 shares of the medical equipment provider’s stock after selling 3,512 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Zimmer Biomet were worth $2,778,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Metis Global Partners LLC increased its holdings in shares of Zimmer Biomet by 4.0% during the 4th quarter. Metis Global Partners LLC now owns 12,361 shares of the medical equipment provider’s stock worth $1,306,000 after purchasing an additional 476 shares during the period. US Bancorp DE increased its holdings in shares of Zimmer Biomet by 7.3% during the 4th quarter. US Bancorp DE now owns 77,317 shares of the medical equipment provider’s stock worth $8,167,000 after purchasing an additional 5,271 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Zimmer Biomet by 7.1% during the 4th quarter. Fisher Asset Management LLC now owns 5,248 shares of the medical equipment provider’s stock worth $554,000 after purchasing an additional 348 shares during the period. SVB Wealth LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth about $928,000. Finally, QRG Capital Management Inc. increased its holdings in shares of Zimmer Biomet by 5.4% during the 4th quarter. QRG Capital Management Inc. now owns 5,948 shares of the medical equipment provider’s stock worth $628,000 after purchasing an additional 303 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $104.32 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $20.77 billion, a P/E ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02. The firm has a 50 day simple moving average of $105.72 and a 200 day simple moving average of $107.37. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 earnings per share. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analyst Ratings Changes

Several research firms have recently issued reports on ZBH. Raymond James dropped their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.